Molecular elucidation of normal and cancer stem cells towards development of innovative m-CRA therapy for pediatric cancer

2016 Fiscal Year Final Research Report

• Project/Area Number: 25293234
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Pediatrics
• Research Institution: Kagoshima University
• Principal Investigator: Ken-ichiro Kosai 鹿児島大学, 医学部, 教授 (90258418)
• Co-Investigator(Kenkyū-buntansha): 三井 薫 鹿児島大学, 医歯学域医学系, 講師 (40324975) ; 伊地知 暢広 鹿児島大学, 医歯学域医学系, 助教 (80380624) ; 入江 理恵 鹿児島大学, 医歯学域医学系, 助教 (90381178) ; 王 宇清 鹿児島大学, 医歯(薬)学総合研究科, 特任研究員 (20505143)
• Project Period (FY): 2013-04-01 – 2017-03-31
• Keywords: 小児腫瘍学 / 腫瘍溶解性ウイルス / 幹細胞

Outline of Final Research Achievements

We have developed m-CRA-based technology and medicine that is superior to current oncolytic viruses. This study using stem cells produced the meaningful results, leading to clinical application of m-CRA for pediatric cancer. Survivin promoter was strongly activated in the undifferentiated pluripotent stem cells (PSCs) as well as cancer cells, but its activity was decreased in the differentiated PSCs, to which survivin-responsive m-CRA (Surv.m-CRA) exerted less cytotoxicity. A local injection of Surv.m-CRA may not damage normal stem cells, and Sur.m-CRA therapy should be safe for pediatric patients with cancer. These results contributed to the expansion of clinical application of Surv.m-CRA therapy to pediatric patients.

Free Research Field

遺伝子治療・再生医学